Receptor tyrosine kinase therapeutic monoclonal antibodies
SYnAbs generates custom therapeutic monoclonal antibodies to receptor tyrosine kinases (RTKs) thanks to proprietary technologies and unique expertise
SYnabs unique anti-CD25 anti-IL2R therapeutic antibody has shown great promise in clinical trials. SYnAbs antagonist anti-IL2Ra/Tac depletes Tregs for GvHD and cancer treatments.
SYnAbs unique monoclonal antibodies to IL1RAP